Teknos Named Chair of Otolaryngology – Head and Neck Surgery
Ted Teknos, MD, a professor and surgical oncologist at Ohio State since 2008, has been named chair of the Department of Otolaryngology – Head and Neck Surgery in the College of Medicine. Teknos is a member of the Translational Therapeutics Program at the OSUCCC – James and also holds the David E. Schuller, MD, and Carole Schuller Chair in Otolaryngology. His research interests include angiogenesis, refinements in microvascular reconstructive surgery, development of novel therapeutics, and identification of serum and tissue markers for this disease. He has been co-chair of the Task Force on Recurrent and Metastatic Disease for the National Cancer Institute’s Head and Neck Cancer Steering Committee since 2007 and serves as the Medical Director of the OSUCCC – James Campaign. He also has received grants from the National Cancer Institute, the National Comprehensive Cancer Network and the American Cancer Society to support his research on improving outcomes of patients with head and neck cancer.
Large External Grants Will Bolster Research at the OSUCCC – James
\Researchers at the OSUCCC – James recently received from entities within the National Institutes of Health (NIH) a number of large grants totaling several million dollars that will support ongoing efforts to create a cancer-free world. Grant awards include:
- “Breast Cancer Survivors Cardiovascular Risks: Treatment and Behavioral Influences” (Principal Investigator [PI] Janice Kiecolt-Glaser, PhD) – A five-year, $4.3 million grant from the National Cancer Institute (NCI) (CA186720) to follow up on preliminary data suggesting that chemotherapy treatment and depression can enhance cardiovascular risk in breast cancer survivors.
- “Collaborative Human Tissue Network” (PI Leona W. Ayers, MD) – A five-year, $4.2 million NCI grant to organize the resources and experience of Ohio Comprehensive Cancer Centers in consortium to make available pathology remnant biomaterials for basic and early translational cancer research through the National Cancer Institute (NCI) Collaborative Human Tissue Network (CHTN).
- “ITSC for Leukemia: Novel Molecular Strategies for NCTN: Individualized Therapies” (PI Guido Marcucci, MD, and Clara D. Bloomfield, MD) – A five-year, $3.5 million NCI grant to form an Integrated Translational Science Center for Leukemia to support new ideas from outstanding investigators with the goal of revolutionizing leukemia treatment.